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Abstract
Background: Reelin and its downstream signaling members are important modulators of actin and microtubule
cytoskeleton dynamics, a fundamental prerequisite for proper neurodevelopment and adult neuronal functions.
Reductions in Reelin levels have been suggested to contribute to Alzheimer’s disease (AD) pathophysiology. We
have previously reported an age-related reduction in Reelin levels and its accumulation in neuritic varicosities along
the olfactory-limbic tracts, which correlated with cognitive impairments in aged mice. Here, we aimed to
investigate whether a similar Reelin-associated neuropathology is observed in the aged human hippocampus and
whether it correlated with dementia status.
Results: Our immunohistochemical stainings revealed the presence of N- and C-terminus-containing Reelin
fragments in corpora amylacea (CAm), aging-associated spherical deposits. The density of these deposits was
increased in the molecular layer of the subiculum of AD compared to non-demented individuals. Despite the
limitation of a small sample size, our evaluation of several neuronal and glial markers indicates that the presence of
Reelin in CAm might be related to aging-associated impairments in neuronal transport leading to accumulation of
organelles and protein metabolites in neuritic varicosities, as previously suggested by the findings and discussions
in rodents and primates.
Conclusions: Our results indicate that aging- and disease-associated changes in Reelin levels and proteolytic
processing might play a role in the formation of CAm by altering cytoskeletal dynamics. However, its presence may
also be an indicator of a degenerative state of neuritic compartments.
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Background
The increase in human life expectancy has entailed a pro-
nounced rise in age-associated neurodegenerative diseases
with the most prominent form being Alzheimer’s Disease
(AD), affecting over 26 million people worldwide [1].
Despite extensive research performed during the past, no
efficient therapies for this progressive brain disease are
currently available. Most of the scientific approaches were
based on the “amyloid cascade hypothesis” that placed the
β- and γ-secretase-generated amyloid-β peptides as causal
factors of the pathophysiology [2,3]. While this may hold
true for the familial form of AD with its dominant muta-
tions in either the amyloid precursor protein (APP, [4,5])
or presenilin 1 and 2 (PSEN; [6,7]) genes, the initiating
trigger of the aging-associated, sporadic form of AD is still
unknown. Based on recent experimental evidence demon-
strating that multiple exposures to viral-like immune chal-
lenges are sufficient to induce AD-like neuropathology in
aged wild-type mice [8], we were able to identify a crucial
trigger and to reconstruct the temporal-spatial sequence
of pathophysiological changes that characterize the earliest
disease stages. The integration of experimental data of the
last three decades enabled us to substantiate and expand
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our findings to propose a cellular mechanism of the
neuropathological changes and its progression across
interconnected brain areas that characterize sporadic AD
[9,10]. The new hypothesis highlights the detrimental
effect of chronic inflammatory conditions on basic cellular
functions in long-projection neurons of the olfactory-
limbic system during aging. The selective vulnerability of
these neurons includes inflammation-induced impair-
ments in the Reelin-mediated signaling pathway across
these fundamental neuronal networks [10]. By binding to
the apolipoprotein E receptor 2 (ApoER2) and the very
low density lipoprotein receptor (VLDLR) [11,12], the
extracellular matrix protein Reelin regulates cytoskeletal
dynamics essential for migrating neurons [13,14], develop-
ing neurites [15,16] and adult spines [17,18]. The signaling
pathway involves cytosolic cascades that ultimately inhibit
the major tau kinases, Glycogen Synthase Kinase 3β
(GSK3β) and Cyclin-Dependent Kinase 5 (CDK5) [19-21],
as well as activates the LIM1 kinase and increases
n-cofilin phosphorylation [22] to modulate both the
microtubule and actin cytoskeleton, respectively. Engaging
the same signaling pathway, Reelin also exerts a crucial
role at adult synaptic sites by modulating NMDA receptor
functions [23-27]. Recent experimental evidence further
highlighted that Reelin maintains synaptic plasticity by
competing with ApoE4 to prevent the latter from seques-
tering NMDA, AMPA, and ApoER2 receptors in intracel-
lular compartments [27]. In line with the well described
aging-associated synaptic impairments, Reelin expression
has been shown to decline in aging rodents, correlating
with hippocampus-dependent learning and memory per-
formance [28,29]. Furthermore, Reelin accumulates within
neuritic varicosities in both rodents and non-human
primates [28,30], possibly related to the aging associated
decrease in Reelin signaling and its protective modulation
of cytoskeleton dynamics [10]. In agreement with these
experimental data, recent genome wide association studies
performed in elderly, non-demented individuals identified
three single nucleotide polymorphisms (SNPs) in the
Reelin gene that significantly correlated with increased
Tau phosphorylation and concomitant appearance of
neurofibrillary tangles (NFTs) [31]. Moreover, immunohis-
tochemical investigations involving human brains revealed
significantly decreased levels of Reelin in patients with
mild cognitive impairments (MCI) and AD compared to
non-demented subjects [32,33]. Further evidence of
altered Reelin-mediated signaling in AD was provided by
genetic [34] and biochemical studies [35,36] suggesting
that decreased Reelin production may contribute to the
initiation and progression of AD by impairing synaptic
functions, cytoskeleton stability and proper axonal trans-
port. Interestingly, alterations in Reelin glycosylation, its
proteolytic cleavage and degradation, as well as changes in
its mRNA stability were shown to be changed in brain
homogenates of AD patients [35,36], further highlighting
the importance of proper Reelin signaling during aging.
Here, we investigated the localization and levels of
Reelin in the postmortem human brain by selectively
assessing its putative accumulation in neuritic varicosi-
ties in non-demented elderly and patients with AD by
immunohistochemistry and unbiased stereological ana-
lyses. Complementary immunoblotting of corresponding
CSF samples was performed to examine potential alter-
ations in Reelin proteolytic processing.
Methods
Human tissue
Formalin fixed paraffin-embedded hippocampal brain
tissue blocks of eight AD patients and eight age-
matched non-demented individuals were obtained from
the Netherland Brain Bank, Amsterdam, Netherlands
(Table 1). Blocks were de- and re-paraffinized with fresh
paraffin. Serial sections (5 μm) were cut on a sliding
microtome with an inter-section interval of 100 μm.
Cerebral spinal fluid (CSF, obtained postmortem from
the lateral ventricles with an 18GA 3.50 inch spinal
needle) of each subject was thawed and centrifuged at
20’000 rpm for 15 minutes at 4°C, the supernatant
aliquoted and stored at −80°C until further use. Quality
assessments revealed no blood contaminations in the
CSF samples. Additional test tissue for qualitative investiga-
tions included paraffin-embedded sections (cut at 10 μm)
from the hippocampus of 6 non-demented and 6 age-
matched AD patients (kindly provided by Professor
Manuela Neumann, German Center for Neurodegenerative
Diseases (DZNE) Tübingen and Institute of Pathology and
Neuropathology).
Antibodies
The following antibodies were used: mouse monoclonal
anti-Reelin recognizing the N-terminus (clone G10,
MAB 5364, Milipore 1:200 and clone 142, MAB 5366,
Milipore 1:200); mouse monoclonal anti-Reelin anti-
bodies (C-terminal subrepeats 8A and 8B, 1:200 each,
kindly provided by Professor André Goffinet, University
of Louvain Medical School, Brussels, Belgium); rabbit
polyclonal anti-amyloid β (1-40/42), (AB5076; Millipore,
1:200); mouse monoclonal anti APP-A4, clone 22C11
(MAB348 Millipore, 1:500), mouse monoclonal anti-PHF
Tau (clone AT100, MN1060; Thermo Scientific, 1:1000);
polyclonal rabbit anti-Tau pS422 (44-764G, Invitro-
gen,1:1000); rabbit polyclonal anti-GFAP (Z0334, DAKO,
1:2500); mouse monoclonal anti-GFAP (MAB 360,
Millipore, 1:10’000); rabbit polyclonal anti-Iba1 (019–
19741, Wako Pure Chemical, 1:2000); polyclonal rabbit anti-
MAP2(26*) (microtubule-associated protein 2) (AB5622,
Chemicon, 1:2000); polyclonal rabbit anti-Synapsin-1
(A-6442, Molecular Probes, 1:1000); polyclonal rabbit
Notter and Knuesel Acta Neuropathologica Communications 2013, 1:27 Page 2 of 14
http://www.actaneurocomms.org/content/1/1/27
anti-Synaptophysin (A010, DAKO, 1:500); rabbit poly-
clonal anti-α-Synuclein (ab52168, Abcam, 1:250); mouse
monoclonal anti-CD 45 (M0701, 1:100, kindly provided by
Prof. Karl Frei, Department of Neurosurgery, University
Hospital Zürich, Switzerland).
Immunohistochemistry
Immunoperoxidase staining
Sections were deparaffinized in xylol (3 times for 3 mi-
nutes), rehydrated in decreasing ethanol concentrations
(twice 100%, 96%, 70% and twice dH2O for 3 minutes
each) and washed in 50 mM Tris-saline, pH 7.4 (1×Tris).
The following antigen retrieval techniques were applied:
two 5-minute citrate buffer microwave irradiations at
800 W (to visualize Reelin-producing cells with anti-
Reelin 142 antibody, see Additional file 1: Figure S1),
10-minute citrate buffer microwave irradiation at 80°C,
either followed by a 10-minute pepsin treatment [39] or
not, and a 5-minute 95% formic acid treatment (to visua-
lize Aβ plaques). Furthermore, a 10-minute 3% H2O2/
methanol treatment was used to block endogenous perox-
idase reactivity. Sections were then incubated for 30 min in
blocking solution (1×Tris containing 5% normal horse
serum, 5% normal goat serum, 4% of BSA), transferred
to the primary antibody solution (diluted in 1×Tris,
containing 2.5% normal horse serum, 2.5% normal goat
serum, 2% BSA) for overnight incubation at 4°C. Sections
were washed in 1×Tris and incubated for 30 minutes with
biotinylated secondary antibodies (1:200 in same solution
as used for primary antibodies). After 3 washes in 1×Tris,
sections were processed for the DAB immunoperoxidase
using the Avidin-Peroxidase-Complex (ABC, Vectastain
Elite kit) staining techniques as described previously
[40-42]. To visualize cell nuclei and corpora amylacea
(CAm), sections were counterstained with Harry's
Hematoxylin (HHS-128, Sigma-Aldrich; very weak staining
of CAm) or Ehrlich’s Hematoxylin (100 ml dH2O, 100 ml
96% ethanol, 100 ml glycerol, 10 ml glacial acetic acid, 2 g
hematoxylin, 3 g kalialaun, 0.4 g sodium jodate; strongly
reacts with CAm [43], kindly provided by Charlotte Burger,
University of Zurich, Institute for Anatomy). In brief,
sections were incubated for 2 minutes in the Hematoxylin
solution, rinsed in tap water, differentiated in acetic alcohol
and blued in running tap water for 10 minutes, dehydrated
and coverslipped with Eukitt (Erne Chemie). Toloidinblue
staining was performed according to standard protocols.
Immunofluorescence staining
The protocol was identical to the described immuno-
peroxidase staining with the following changes: All
Table 1 Details of human postmortem brain tissue included in the analyses
NBB-Code Sex Age
(years)
PMD
(h.min)
Brain
weight (g)
Braak
stages*
Apoe
genotype
Clinicopathological data pH (csf) [Protein]mg/ml
Controls
07-082§ M 81 7.55 1194 2 0 3/3 Renal insufficiency and decompensatio
cordis
6.23 4.6
00-142 F 82 5.30 1260 1 A 3/2 Myocardial infarct 6.60 3.14
03-061 F 83 5.30 1274 1 B 3/2 Squamous cell carcinoma of the left maxilla 6.48 3.62
05-083 F 85 5.00 1217 1 B 3/3 Multi organ failure after a ruptured
abdominal aneurysm
6.72 4.46
98-157§ M 85 5.13 1383 2 A 3/2 Cardiac tamponade 6.23 2.92
04-061 F 88 6.15 1121 ? B 3/3 Old age 6.98 2.79
96-105§ M 88 5.40 1120 4 4/3 Cardiac arrest 6.65 1.4
96-044§ F 90 5.50 1046 2 A 3/3 unknown 7.00 2.79
AD
06-013§ M 81 4.50 1193 4 C 4/4 Dehydration, sepsis? 6.42 3.02
09-105 F 82 5.25 999 5 C n/a Heart failure 6.08 3.63
00-138§ F 84 5.15 1098 5 C 3/3 Pneumonia with dehydration 6.65 2.2
97-093 M 86 5.35 1250 5 C 4/3 CVA/Myocardial infarction 6.39 1.93
06-044 F 86 5.55 930 4 B 4/3 Cachexia 6.85 1.8
04-064 F 88 6.25 1079 5 C 3/3 Organ failure due to dehydration 6.60 2.88
97-003§ M 88 5.10 984 5 B 4/3 Pneumonia 6.45 2.38
96-049 F 90 3.50 925 5 4/3 Dehydration 7.02 2.81
*According to [37,38].
PMD = postmortem delay.
§ Tissue blocks containing hippocampus and EC.
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washing steps and antibody dilutions were done in
phosphate-buffered saline (PBS) at pH 7.4. Sections were
blocked for 1 hour and incubated for 45 min with the
secondary antibodies (coupled to either Alexa Fluor488
or Cy3 (dilution 1:1000 and 1:500, respectively; Molecu-
lar Probes, Invitrogen). To reduce lipofuscin-associated
auto-fluorescence in aged cells, sections were incubated
in 0.1% Sudan Black (Carl Roth GmbH) dissolved in 70%
methanol for 2 minutes, briefly washed with PBS and
air-dried [44]. Sections were then coverslipped with
Dako-DAPI solution (Dako) or ProLong Gold Antifade
reagent (Invitrogen) to visualize cell nuclei.
Microscopy and image acquisition
Immunoperoxidase-stained sections were scanned and
visualized with an automated upright slide-scanning
microscope (Zeiss) in brightfield mode and the Pannora-
mic Viewer 1.8.3.0 (3D Histotech Ltd), respectively. High
magnification images were acquired with a brightfield
light microscope (Axioscop 2, Zeiss) connected to a digital
camera (AxioCam, Zeiss) and captured with AxioVision
software (Version 4.5., Zeiss), or with a confocal micro-
scope (LSM 710, Zeiss) and processed with Imaris 7.1.1
software (Bitplane Inc.) and Adobe Photoshop CS5
(Adobe) software.
Quantitative and statistical analyses
Stereological estimations of Reelin-positive CAm area
and density were performed using the Stereo Investi-
gator 10.50 software (Microbrightfield Bioscience). Two
sections with an intersection distance of 200 μm were
used for quantification. The following regions were
included for the analyses based on the density of the
deposits (Figure 1): fornix, stratum lacunosum mole-
culare (SLM), layer I of subiculum, layer I of pre/
parasubiculum and layer I of entorhinal cortex (EC)
[45,46]. Other areas of the hippocampal formation were
not included to minimize measurement errors. The
Cavalieri estimator with a grid spacing of 100 μm was
used to estimate the area of the region of interest. For
fractionator sampling, an unbiased counting frame sized
between 80 and 200 μm (depending on the deposit den-
sity) was applied to estimate the Reelin-positive CAm
profile density. Concomitantly, the individual CAm areas
were estimated using the nucleator with 4 rays. The area
fraction (AF) was calculated using the following equa-
tion: AF = NCA × ACA/Atot, where NCA is the estimated
profile number of Reelin-positive CAm within the mea-
sured area, ACA is the mean area of CAm within the
measured area, and Atot is the total area measured. Stat-
istical analysis of the area and density of Reelin-positive
CAm was performed using StatView software. For each
brain region, a factorial ANOVA was performed with
Group (2 levels: ND and AD) and Deposit type (2 levels:
filled vs hollow) as independent variables, and AF
(area fraction), ACA (mean CAm size), NCA (estimated
number of Reelin-positive CAm) as dependent variables.
Pearson’s product moment correlations were performed
between Reelin-positive CAm (AF, filled and hollow
combined) and Western blot data (full-length Reelin,
Figure 1 Reelin immunoreactivity in the aged human hippocampal formation. A) Reelin (G10 antibody) immunoperoxidase labeling in
combination with hematoxylin (Ehrlich) counterstaining. The tissue section was obtained from an 88 year-old ND individual. The color-coding
represents the areas included in the stereological analysis: 1=fornix, 2=stratum lacunosum moleculare (SLM), 3=molecular layer of subiculum,
4=molecular layer of pre/parasubiculum, 5=molecular layer of entorhinal cortex (EC). B) Higher magnification view of Reelin-positive deposits in
the fornix. Arrow points to a filled deposit, arrowhead indicates a hollow deposit. C) Reelin (G10) immunoperoxidase labeling combined with
toloidinblue counterstaining in the fornix border area. Tissue section was obtained from an 80 year-old AD patient. D) Control staining using
isogenic IgGs (mouse anti-human CD45 antibody) following antigen retrieval (microwave irradiation in citrate buffer plus pepsin pretreatment)
and Hematoxylin (Harrys) counterstaining. Brain section was obtained from a 79 year-old ND individual. Arrowhead points to a CD45-negative
deposit, insert represents a CD45-positive lymphocyte associated with a brain capillary. E) Control staining without primary antibody following
antigen retrieval and Hematoxylin/Eosin counterstaining. Brain section was obtained from an 81 year-old ND individual. Arrowhead points to an
immune-negative deposit. Scale bars: A = 2 mm, B - D = 30 μm.
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NR2, NR6 and 60 kDa fragments). Statistical significance
was set at p<0.05.
Western blot analysis
Protein concentrations of the CSF samples were mea-
sured using NanoDrop (Table 1). Equal volumes of CSF
were analyzed. The sample preparation was performed
as previously described [47]. Western blotting was done
as described [47] with the following adaptations: 3–8%
Tris-Acetate Midi Gels were used (NuPAGE Novex
Tris-Acetate Midi Gel). The electrophoresis was perfor-
med using the Xcell4 SureLock Midi-Cell system (Cat.
No. WR0100, Invitrogen). Proteins were blotted onto
PVDF membranes using the Novex Semi-Dry Blotter
(Cat.No. SD1000, Invitrogen). Films were scanned and
analyzed using ImageJ Launcher software; intensities of
bands were measured (area under the curve, AUC) and
quantified. Reelin immunoreactivity was statistically
compared between ND and AD subjects using the non-
parametrical Mann–Whitney U test using StatView soft-
ware. Statistical significance was set at p<0.05. Scanned
films were processed with Adobe Photoshop CS5 for
visual display (Adobe software).
Results
Reelin immunoreactivity in the human hippocampal
formation
To analyze the localization and levels of Reelin in the
human hippocampal formation we performed an immu-
noperoxidase staining using Reelin antibodies recogni-
zing the N- (G10 and 142) and C-terminal domains of
Reelin (R12/14), to identify putative enrichments in
proteolytic fragments of Reelin. Paraffin-embedded sec-
tions of ND and AD (n = 8, Table 1) were employed. We
detected spherical Reelin-positive structures varying in
their size from approximately 60 up to 250 μm2 predom-
inantly located in fiber-rich structures (Figure 1 and
Additional file 1: Figure S1) in both groups of subjects.
They were most abundant in the fornix, enriched in
myelinated axons of afferent and efferent projection
neurons. A high density of these immunoreactive
deposits was also evident in the neuropil of layer I of the
pre-/parasubiculum and subiculum. Fewer deposits were
detected in layer I of the entorhinal cortex (EC) and the
stratum lacunosum moleculare (SLM) of the hippocam-
pus (see Figure 1A for overview). In some cases, Reelin
deposits were located in the hilus and rarely also in the
pyramidal layer of CA3 and CA1. The immunoreactive
signals were specific for Reelin, since control stainings
with isotypic IgGs (mouse anti-human CD45) or the
omission of primary antibodies did not yield any specific
labeling (Figure 1D-E). The control staining using the
well-characterized anti-CD45 antibody also indicated
that the Reelin-immunoreactivity was not linked to
putative invading lymphocytes. Based on their distinct
morphology and enrichment in fiber-rich structures,
however, we reasoned that they might be related to
corpora amylacea (Cam), the age-related spherical bodies
suggested to contain a collection of neuronal breakdown
products including aggregated proteins and abnormal
glycogen bodies [48,49]. Indeed, hematoxylin (according
to Ehrlich) and toloidinblue counterstaining identified
the Reelin-positive structures as CAm. While all antigen
retrieval techniques applied here diminished the Hema-
toxylin or Toloidinblue stainings, the immunoreactive
anti-Reelin signal associated with CAm was never
affected (see Methods and Additional file 2: Figure S2).
Reelin-positive deposits in AD versus non-demented
subjects
With our staining protocol, we were able to identify two
different types of Reelin-positive CAm: 1) A filled type;
with the entire area of CAm being Reelin immunoreac-
tive (Figure 1B arrow), and 2) a hollow type; with Reelin
immunoreactivity being located around the acidic core
of CAm (Figure 1B arrowhead). Here, we were interested
to determine whether their density differed between ND
and AD subjects. We performed a stereological analysis
within selected areas of the hippocampal formation
(Figure 1). The statistical evaluation of Area Fraction
(AF) using a one-way ANOVA revealed a significant
increase in the area covered by the deposits in AD patients
compared to ND controls in the molecular layer of the
subiculum (F(1,28)=4.31, p=0.047). A similar elevation in
deposit area in AD versus NA subjects was seen in the
pre/parasubiculum, however, the ANOVA only yielded a
statistical trend (F(1,26)=3.21, p=0.085; Figure 2C). No
statistical group difference regarding the density of Reelin/
CAm was evident in the other brain areas (all F<0.93, all
p>0.36). The statistical analysis, however, revealed a
significantly higher density of the filled compared to the
hollow type in all areas investigated (fornix: F(1,26)=11.47,
p=0.002; SLM: F(1,28)=14.34, p=0.001; subiculum:
F(1,28)=15.52, p=0.001; pre/parasubiculum: F(1,26)=13.52,
p=0.001; EC: F(1,10)=20.95, p=0.001), that was independent
of the dementia status (Figure 2). Despite this dominance
of filled deposits, the significant increase in total amount
of deposits in the subiculum molecular layer in AD was
not solely attributed to filled deposits (ANOVA: group ×
type interaction: F(1,28)=2.00, p=0.168) but related to a
concomitant increase in both types of deposits.
Reelin levels in the human cerebral spinal fluid (CSF)
To assess whether the immunohistochemical findings
correlate with the levels of Reelin and its physiologically
produced proteolytic fragments in the CSF, previously in-
vestigated in AD and ND subjects but yielding conflicting
results [36,50,51], we performed a biochemical analysis of
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the CSF samples collected for each individual of our study.
Besides the well-described immunoreactive bands repre-
senting full-length Reelin, the NR6 (310 kDa) and NR2
(180 kDa) fragments, we detected an additional band
running at around 60 kDa. This recently described novel
N-terminal Reelin fragment [47] likely represents the
ADAMTS-5-mediated degradation product of Reelin
(Figure 3A) that is enriched in aged brain tissue homo-
genates [47] and detected upon internalization (TN,
unpublished findings). Semi-quantitative analysis of two
repeated experiments revealed high between-subjects
variability and no significant differences regarding the
levels of Reelin and the three proteolytic fragments
emerged between AD and ND subjects (Figure 3B). How-
ever, despite the unknown causal link and the limitations
of our sample size, a correlation analyses highlighted a
significant relationship between the levels of the 60 kDa
fragment and the overall CAm density in subiculum and
pre/parasubiculum in ND subjects (subiculum: r=0.857,
p=0.004; pre/parasubiculum: r=0.845, p=0.006) that was
lost in AD patient (subiculum: r=0.098, p=0.826: pre/
parasubiculum: r=0.275, p=0.529), pointing to putative
alterations in Reelin proteolytic degradation in AD. None
of the other parameters (subfields, Reelin fragments)
yielded any significant relationships and no confounding
effect of the postmortem interval, pH, brain size or ApoE
genotype contributed to this effect.
Levels of AD-relevant proteins in Reelin-positive CAm
Based on the Reelin-dependent modulation of several
AD-relevant pathways, including APP proteolytic
processing [52,53] and Tau phosphorylation [8,52], we
were interested in determining whether these and other
disease-associated proteins were present in the aging-
associated Reelin-CAm deposits. Double-immunofluo-
rescence stainings using antibodies raised against the
N-terminal domain of APP and β-amyloid sequence 1-
40/42 (Aβ1–40/42) or anti-Aβ1–40/42 in combination with
anti-Reelin antibodies revealed their co-localization in
most CAm in all areas independent of disease state
(Figure 4A). However, the intensity varied depending on
the antigen retrieval technique used, in line with pre-
vious reports using paraffin-embedded postmortem
human brain samples [54,55]. For both, N-terminal APP
Figure 2 Summary of stereological analyses of Reelin-positive deposits in ND versus AD individuals. A-E) Scatter plots of the estimated
density of filled and hollow deposits in different areas in the human hippocampus representing the % area covered by Reelin deposits in relation
to the total region of interest (AF, Area Fraction). Horizontal lines represent group average. Statistical analysis yielded a significant group effect for
the subiculum (F(1.28)=4.312, p=0.047), and showed a similar trend for the pre/parasubiculum (F(1,26)=3.21, p=0.085). Note that 4 out of 8 ND and 5
out of 8 AD hippocampi blocks were dissected at a level where no EC was present. F) Overview of estimated filled and hollow deposit densities
across the five brain areas analyzed. Values are displayed in box plot graphs, with the box dimension indicating the 75th (top) and 25th
percentile (bottom) and the mean line. The upper and lower error bars indicate the minimum and maximum, respectively. One way ANOVA
analysis revealed a significant main effect of deposit type in all areas analyzed that was independent of the dementia status: 1) fornix:
F(1,26)=11.45, p=0.002; 2) SLM: F(1,28)=14.34, p=0.001; 3) subiculum: F(1,28)=15.52, p=0.001; 4) pre/parasubiculum: F(1,26)=13.52, p=0.001; 5) entorhinal
cortex: F(1,10)=20.95, p=0.001, statistical significance was set at p<0.05.
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and Aβ1–40/42 antibodies the antigen retrieval methods
applied here either strongly decreased the staining inten-
sity (citrate irradiation and pepsin treatment) or com-
pletely diminished it (95% FA; Additional file 2: Figure S2)
in comparison to non-pretreated sections, suggesting the
presence of soluble APP and/or APP fragments rather
than Aβ aggregates. Double immunofluorescence stainings
using anti-Tau, phosphorylated Tau (pTau) or paired
helical filaments (PHF) in combination with anti-Reelin
antibodies revealed the presence of Tau, however, no
enrichment in phosphorylated Tau species in Reelin-
positive CAm (Figure 4, Additional file 2: Figure S2). To
confirm and further investigate their origin, we performed
double-immunofluorescence staining using additional
antibodies recognizing synaptic, axonal and dendri-
tic proteins. In accordance with previous findings α-
Synuclein [56], our double-immunofluorescence staining
confirmed the presence of α-Synuclein in Reelin-positive
CAm. As with the Aβ1–40/42 antibodies, the signal inten-
sity dropped upon antigen retrieval technique (Additional
file 2: Figure S2). However, anti-Synapsin-1 and anti-
Synaptophysin stainings did not show a positive signal of
these two abundant synaptic proteins within CAm
(Figure 5). On the other hand, the dendritic marker,
MAP2, was detected in CAm using immunoperoxidase
staining (Figure 5), confirming a neuronal origin and
indicating that CAm may originate from both dendritic
and axonal compartments. Based on previous findings
reporting an association of CAm with astroglia [48], we
were interested in determining whether Reelin-positive
CAm show a similar relationship to glial cells. To this end
we performed an immunhistochemical analysis using anti-
bodies against glial fibrillary acidic proteins (GFAP) to
stain astrocytes as well as an anti-Iba1 antibody to label
microglia. As reported, the GFAP immunoreactivity was
highest in all fiber-rich structures, as well as prominent in
glial endfeet enclosing the cerebral vasculature vessels and
ventricle walls (Figure 6). In areas with high labeling,
GFAP immunoreactivity was found in association with
CAm. However, the glial marker was found to be
restricted to the border of deposits, but was not associated
with any of the other markers that were enriched in CAm,
such as APP, Aβ or α-Synuclein. No co-association of Iba1
with CAm was obtained by either immunoperoxidase
or -fluorescence stainings. Rather, the staining intensity
was homogenous across all areas, indicating that these
aging-associated neuronal structures are inert and do not
provoke a microglia activation.
Discussion
Here we describe for the first time the presence of the
extracellular matrix protein Reelin within spherical
depositions in the human hippocampal formation. Our
immunohistochemical stainings revealed the presence of
considerable amounts of N- and C-terminus-containing
Reelin fragments in these deposits. Stereological analyses
indicated that their density in the hippocampal forma-
tion is largely independent of the dementia status;
however, it revealed a trend towards higher levels in
patients with AD and a putative link to alterations in
Reelin proteolytic processing. Based on hematoxylin and
toluidinblue labeling and their distinct morphology, it is
highly conceivable that Reelin and its fragments consti-
tute a major component of CAm, a prominent structure
of the aging human brain whose origin and biological
significance in the CNS is poorly understood. In the
Figure 3 Reelin levels in the CSF. A) Anti-Reelin 142 immunoreactive signals on Western blots at low exposure time (40 seconds) to visualize
the NR2 fragment. A’) Higher exposure time (18 minutes) of the same blot as A to visualize full-length (~460 kDa), NR6 (~ 310 kDa) and the
additional band at ~ 60 kD. Images of immunoblots were cut in half to separate ND from AD for visual display. The short vertical lines at the
bottom of the blot indicate joined bands for visual presentation. The HiMark Pre-Stained Standard was used as ladder. B) Semi-quantitative
analysis of the levels of full-length Reelin and its proteolytic fragments in the CNS. Scatter plots representing relative optical densities expressed in
arbitrary units (AU) of CSF samples obtained from ND and AD individuals. Lines represent the group median. Mann–Whitney U-test revealed no
significant differences between groups.
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Figure 4 AD-relevant proteins are present in CAm. Representative images of double immunofluorescence labeling involving brain sections
obtained from an 82 year-old ND individual counterstained with the nuclear dye DAPI (blue). Red channels show the anti-Reelin (antibody 142;
A, C, D, E), anti-N-APP (B), and anti-PHF Tau (paired helical filament, F) stainings. Green channels depict the anti-Aβ1–40/42 (A’-B’), anti-α-Synuclein
(C’, F’), anti Tau (D’) and anti-pTau (E’) signals. Merged channels are shown in A”-F”. Inserts in E’ and F highlight neurofibrillary tangles in CA1
region stained with anti-pTau and anti-PHF Tau antibodies, respectively. Scale bars = 10 μm.
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following, we summarize the current status of the CAm
literature and discuss the presence and putative role of
Reelin in their formation in the human hippocampal
formation.
Aging-associated CAm in the human hippocampal
formation
Despite the numerous studies, the role of CAm during
aging and neurological diseases has remained obscure.
They are commonly seen in the glial feltwork of subpial,
subependymal, and perivascular regions, but can also be
detected in fiber-rich areas in the CNS, most promi-
nently within the hippocampal formation [48]. The major
components of CAm are glucose polymers, presumably
linked to aging associated glucose metabolism defects,
peptides and proteins (approximately 4%), many of which
have been linked to cellular stress responses [56-58].
Several studies indicated that they evolve from neurons,
astrocytes or oligodendrocytes due to the presence of cell-
specific proteins [48,49,59,60]. However, it is currently
Figure 5 Dendritic and synaptic proteins in the aged human hippocampus: Differential association with CAm. Immunoperoxidase-
hematoxylin staining of brain sections obtained from an 85 year-old ND individual. A) Representative images of the CA2 subfield and fornix (A’)
labeled with the dendritic cytoskeletal marker anti-MAP2. Note the strong immunoreactivity in pyramidal cell bodies and dendrites, as well as
CAm (A’). B-C) Immunoperoxidase staining using anti-Synapsin-1 (B) and anti-Synaptophysin antibodies (C) depicting the CA2 pyramidal cell
layer (B, C), the dentate gyrus molecular layer (B’, C’) and the fornix (B”, C”). While a characteristic synaptic immunoreactivity of both markers
was evident in the hippocampus proper and dentate gyrus, no accumulation of these synaptic proteins was seen in CAm. Scale bars:
A-C = 30 μm, A’-C’ = 30 μm.
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unclear whether their glial association is the result of
phagocytosis of remnants of degenerated neurons/neurites
and vascular metabolites [49,61] or an indicator of glia
pathophysiology/degeneration [62]. In line with these data,
neurological and neurodegenerative diseases such as
temporal lobe epilepsy, multiple sclerosis, and AD are
characterized by elevated levels CAm [61,63], and these
spherical bodies were shown to correlate with neuronal
loss associated with hippocampal sclerosis [63]. The
frequent detection of CAm within axons and terminal
neurites in the aging ocular system [64], as well as the
prominent accumulation of axonal proteins including Tau
[56,65], APP [66], and α-Synuclein [56], indicate that they
may form in response to cellular stress and/or aging-
related impairments in cytoskeletal stability and axonal
transport that ultimately lead to axonal swellings, a
mechanism recently proposed for amyloid plaque forma-
tion in AD [9].
Reelin accumulates in two types of CAm – link to its
expression pattern?
Intriguingly, many of the areas enriched in CAm overlap
with the localization of Reelin. This relates to the well
characterized cell types in the murine brain that are part
of the entorhino-hippocampal, lateral olfactory and
retino-collicular tract as well as the parallel fiber system
of the cerebellum [67-71]. Furthermore, in vitro studies
reported the expression of Reelin in progenitor cells of
oligodendrocytes as well as mature oligodendrocytes
[72], highlighting the possibility that the Reelin immuno-
reactivity associated with CAm in fiber-rich areas like
the fornix may stem from its production and secretion
by progenitors of oligodendrocytes and oligodendrocytes
[72]. Studies in primates identified additional areas with
Reelin-positive cells showing a wider distribution of
Reelin throughout cortical areas than in any other
species, indicating that Reelin influences most cerebral
circuits in higher mammals [73]. Findings in macaque
monkeys showed strong Reelin immunoreactive soma of
Cajal-Retzius cells located in layer I, pyramidal neurons
in EC layer II, and interneurons of the subicular com-
plex molecular layer (subiculum, pre/parasubiculum),
areas which harbor considerable amounts of Reelin-
positive CAm. It is conceivable that these cells, shown
to degenerate during preclinical stages of AD [74-76] are
a major source of Reelin that is detected within CAm. In
line with the findings that Reelin is transported along
axons and secreted to act on postsynaptic cells [69-71],
the deposits located in the SLM, the projection zone of
the layer II pyramidal cells, are most likely distal axonal
accumulations of Reelin. It is conceivable that aging-
associated impairments of axonal stability and hence
axonal transport increase the likelihood of accumu-
lations of transported proteins and organelles. This may
Figure 6 Association of astrocytes but not microglia with Reelin/CAm deposits. Immunohistochemical analyses involving brain sections
obtained from an 82 year-old ND individual. A) Representative image of the fornix labeled with anti-GFAP antibodies and hematoxylin (Ehrlich)
staining. Note the GFAP immunoreactivity enclosing the CAm in the dense glial network. Insert represents a Reelin/CAm deposit in an area with
low GFAP intensity. B) Double immunofluorescence staining with anti-Reelin antibody (142, red, B’) and anti-GFAP antibody (green, B”). Nuclei
are visualized with DAPI-enriched mounting medium. C) Immunoperoxidase staining using anti-Iba1 antibody and hematoxylin (Ehrlich)
counterstaining. The pretreatment of the tissue sections with 10 minute citrate irradiation completely diminishes the CAm labeling (arrowhead).
D) Double immunofluorescence staining using anti-Reelin antibody (142, red, D’) and anti-Iba1 antibody (green, D’). Scale bars: A, C = 30 μm;
B, D = 10 μm.
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aggravate during phases of cellular stress that is
frequently accompanied by increased levels in damaged
and misfolded proteins, which show a much higher
propensity to aggregate (for recent review, see [9]). It is
therefore plausible, that the decrease in Reelin levels
during aging [28,32,33] with its concomitant in- and
decrease in Tau [12,52] and n-cofilin phosphorylation
[22], respectively, may reduce axonal and dendritic cyto-
skeletal stabilities and strongly impair transport from
and to synaptic sites. In agreement with this hypothesis,
our data showed that highly abundant and cellular
stress-induced/associated axonal proteins such as APP
and α-Synuclein co-accumulate with Reelin in CAm.
Our findings that the formic acid pretreatment (used to
detect Aβ peptides in amyloid plaques) abolished the
anti-Aβ1–40/42 immunoreactivity in CAm indicates that
soluble APP and/or APP fragments, rather than Aβ
peptide aggregates, accumulate in CAm, which is in line
with previous reports [66]. The presence of MAP2 in
CAm may be indicative of dendritic varicosities or
related to missorting of this dendritic cytoskeletal pro-
tein into axonal compartments. In support of a putative
protein mistargeting, we did not find evidence of phos-
phorylated Tau species in Reelin-positive CAm, a result
that is also in agreement with previous studies [56,65].
This phenomenon may also be linked to potential
dephosphorylation of Tau in the putative acidic [8] and/
or protein cross-linking and polymerization environment
[56], a potential scenario that would also explain the lack
of Synapsin-1 and Synaptophysin immunoreactivity in
CAm. It is further conceivable that the change in
glucose metabolism – potentially linked to aging-related
alterations in glial support – promote the formation of
abnormal polysaccharide chains that further block
axonal transport. The presence of Reelin in the filled
type of CAm could be indicative of such an axonal
pathophysiology as previously suggested by the findings
and discussions in rodents and primates [9,30,77]. How-
ever, the detection of Reelin in the hollow type shows
that the core of CAm can be formed independently of
Reelin and could indicate that this rare type of spheroid
might be linked to the accumulation of Reelin in astro-
cytic endfeet [39]. This is in agreement with the findings
shown here and by others that GFAP-positive astrocytes
are associated with but not found in the core of CAm
[59]. This hypothesis is also in line with our previous
findings, demonstrating with 3D-electron microscopy
that Reelin-positive varicosities can be extruded from
neurites and detected in astrocytic endfeet, potentially
related to phagocytosis [30]. The lack of CAm-associated
microglia activation reported here is also indicative that
these spherical bodies are inert, despite the presence of
putative toxic peptides, proteins and cellular metabolites
[61]. The distinct association of Reelin at the boarder of
CAm – particularly prominent in the hollow type - may
be linked to its extracellular secretion and accumulation
around CAm that precludes a microglia response.
Altogether, this may explain why CAm – despite their
close association with aging-associated neurodegenerative
processes linked to impairments in glucose metabolism,
protein synthesis, transport and degradation – have no
major effects on the physiology of neighboring neurons. It
would be highly relevant to assess the levels of Reelin as-
sociated with CAm localized outside the hippocampal
formation (i.e. hypothalamic nuclei), which have been
reported to display pronounced cytoskeletal alterations
during the course of aging and AD [78].
Reelin levels and deposits in AD compared to ND
individuals
Previous reports indicated that several neurological and
neurodegenerative conditions are accompanied by an
increase in CAm, potentially linked to higher levels of
cellular stress. However, quantitative data are largely
missing. Here, we intended to assess the density of
Reelin-positive CAm with an unbiased stereological
approach involving five distinct areas of the hippocampal
formation, complemented with immunoblot analyses to
measure the Reelin levels in CSF samples of the same
ND and AD individuals. Our stereological analysis
revealed that the total amount of Reelin-positive CAm –
independent of the type of deposit - was found to be
increased in the subicular complex of AD compared to
ND individuals. However, due to the small cohort and
the high between subject-variability, only the density in
the subiculum molecular layer yielded a significant
group effect. Despite the limitation due to the small
sample size, our data indicate the increase in CAm density
may reflect the aggravation the aging-related impairments
in cellular functions that result in increased intracellular
accumulation of missorted, misfolded or poorly degraded
proteins which is known to be increased in AD [9]. It is
very likely that putative differences in other areas mea-
sured were covered by an aging effect, as there is a clear
age-dependent increase in the number of CAm [48]. Cur-
rently, it is unknown how these histopathological changes
relate to the level of Reelin protein and its proteolytic
products in the CSF. While our assessment of full-length
Reelin and its proteolytic fragments in the CSF revealed
no statistical differences between groups, a correlation
analyses highlighted a significant relationship between the
levels of the 60kDa fragment and the overall CAm density
in the susubiculum and pre/parasubiculum in ND subjects
but not AD patients. While a higher sample size is abso-
lutely required to substantiate this finding, the preliminary
data indicate that the accumulation of Reelin in CAm
might be related to its proteolytic degradation, a pheno-
menon that appears to be altered in AD versus ND
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subjects. It will also be highly relevant to assess Reelin
levels in CSF and brain tissue homogenates in younger
cohorts of ND subjects, as well as MCI and early stages
of AD, which is expected to show larger differences to
age-matched ND individuals. Differences in the age
range of the subjects included in previous studies may
have also accounted for the conflicting results regar-
ding the levels of Reelin and its fragments in the CSF
published earlier [36,50,51]. It would be therefore
highly relevant to investigate the levels of Reelin and all
its proteolytic fragments (including the 60 kDa pro-
duct) and its putative enrichment in neuritic varicosi-
ties in a substantially larger cohort of human subjects
across aging and AD.
Conclusion
Altogether, our results indicate that aging- and
disease-associated changes in Reelin levels and pro-
teolytic processing might play a role in the formation
of CAm by altering cytoskeletal dynamics. Its pre-
sence may also be an indicator of a degenerative state
of neuritic compartments. However, this remains to
be experimentally determined using preclinical models
of aging and AD.
Appendix
Additional text
We detected the Reelin-positive deposits using various anti-
bodies raised against different Reelin epitopes (Additional
file 1: Figure S1A-C). Reelin deposits were stained with all
antibodies used, independently of the antigen retrieval
technique. To visualize CAm with hematoxylin or toloi-
dinblue, antigen retrieval was omitted in order to maintain
the coloration. Figure 1E illustrates the high morpho-
logical variations in Reelin/CAm deposits. Besides the
prominent staining of Reelin within deposits, we also
detected intracellular Reelin immunoreactivity in pyra-
midal cells of the cornu ammonis, particularly in CA3 and
to lesser extent CA1 pyramidal cells, using N-terminal
but not C-terminal targeting antibodies (Additional file 1:
Figure S1F), in line with a previous report [31]. These
immunoreactive signals were, however, only seen using
an antigen retrieval approach involving microwave irradi-
ation in citrate buffer followed by pepsin pretreatment
(see Methods). Chromatin filters and high magnification
microscopy revealed Reelin to be present within cytosolic
vesicles (insert, Additional file 1: Figure S1F). To visualize
Reelin-expressing cells, which were sparse in our cohort
of aged non-demented individuals and shown to further
decrease in AD patients [32,79], repeated microwave
irradiation in citrate buffer had to be applied (Additional
file 1: Figure S1C, insert).
Additional files
Additional file 1: Figure S1. Immunoperoxidase stainings of paraffin-
embedded hippocampal brain sections. A) Anti-Reelin immunoreactivity
(G10 antibody) in tissue section obtained from a 63 year-old ND
individual following antigen retrieval with microwave irradiation in citrate
buffer and pepsin pretreatment. B) Brain sections of an 89 year-old AD
patient, processed for antigen retrieval (citrate and pepsin pretreatment),
stained with anti-Reelin (142) antibodies. C) Anti-Reelin (142 antibody)
immunoperoxidase and hematoxylin staining of tissue section obtained
from an 88 year-old ND individual following repeated microwave
irradiation in citrate buffer. Insert shows a Reelin-expressing cell located
in SLM. D) Reelin immunoreactivity (R12/14 antibodies) in tissue section
of a ND individual (63 years old) pretreated with citrate and pepsin. E)
Morphological variations of Reelin-positive deposits located in five brain
regions included in the stereological analysis. Representative pictures of
immunoperoxidase staining using anti-Reelin antibody (G10) combined
with microwave irradiation in citrate buffer and pepsin pretreatments. F)
Reelin immunoreactivity in pyramidal cells of AD patient (80 years old)
visualized with anti-Reelin antibody (G10) following citrate/pepsin
pretreatments. G) Reelin immunoreactivity (R12/14 antibodies) in tissue
section of an AD individual (78 years old) pretreated with citrate and
pepsin. Arrowheads point to cytosolic vesicles with immunopositive
Reelin labeling. Scale bars: A-D, F =30 μm; E = 25 μm.
Additional file 2: Figure S2. Antigen retrieval and its effect on staining
intensities of AD-relevant proteins in CAm. Representative images of
immunofluorescence staining involving brain sections obtained from a
ND individual (82 years old) counterstained with the nuclear dye DAPI
(blue). Antigen retrieval involved either microwave irradiation in citrate
buffer followed by pepsin incubation (A-B) or a 95% formic acid (FA)
pretreatment (C). A) Double labeling using anti-α-Synuclein (red, A) and
anti-Reelin (G10, green, A’) antibodies, merged in A”. B) Anti-Aβ1–40/42
antibody (red, B) combined with anti-Reelin antibodies (G10, green, B’)
show a large degree of overlap (B”, merged). C) Double
immunofluorescence staining using anti-pTau (red, C) and anti-Aβ1–40/42
antibodies (green, C’). Note that the FA treatment destroys the anti-Aβ1–
40/42 signal in the CAm but not in amyloid deposits (arrowhead). The
pixel brightness is increased in the merged channels to visualize the
presence of the immunonegative deposits (C”). Scale bars = 10 μm.
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